New Danish manufacturer Nordisk is looking for an extension for the patent of the drug Ozempic, which should expire in July 2026 in Brazil. The information is from the newspaper The globe.
The movement occurs at a time when other Brazilian pharmacists are preparing to launch similar versions of the drug, which is widely used for weight control.
The company’s attempt to prolong intellectual property protection aims to ensure exclusivity in drug production and marketing, while competition promises to make treatment more accessible.
Read more:
Novo Nordisk argues that Brazilian law was not fairly applied in relation to Ozempic, noting that the patent was granted only 13 years after the request at the National Institute of Industrial Property (INPI).
The company has already appealed to court to try to maintain the patent by 2036, but this request was denied, since the Federal Supreme Court (STF) declared unconstitutional the extension of patents based on previous legislation.
Continues after advertising
With the imminent expiration of the patent, Brazilian laboratories, such as EMS and Biomm, are mobilizing to launch medicines based on Semaglutida, the active ingredient of Ozempic.
Biomm has already signed an agreement with Biocon, from India, to bring Semaglutida to Brazil, while EMS received anvisa permission to produce liraglutide -based analog drugs, a substance of the same Ozepic class.
Phatacist Prati-Donaduzzi also announced that it is conducting research to develop a generic version of the drug, with the expectation that studies will be completed as soon as generic production is authorized.
Continues after advertising
According to experts, the entry of new competitors in the market will result in a drop in prices, making treatment more affordable for consumers. Currently, Ozepic is marketed for values ranging from $ 700 to $ 1,000.
